Detailed analysis of the failed TTR cardiomyopathy trial published in NEJM casts doubt on the benefit of RNA silencer therapies beyond standard care, with impli

Lisraya is the first approval for the Roivant subsidiary's drug licensed from Pfizer, targeting multiple rare inflammatory conditions.

The capital raise follows a key study win for Moderna's pipeline, alongside regulatory clearance for new COVID shots.

Rasonque is the first therapy to target a genetic driver of advanced pancreatic cancer, with analysts projecting blockbuster sales.

After 27 years to win its first drug approval, Cytokinetics' new data could bring a second drug to market quickly for heart condition treatment.

Positive results could unlock a blockbuster opportunity for Tezspire, expanding its use beyond asthma beyond asthma.

The clearance covers a redesigned e-cigarette with built-in age verification aimed at preventing underage use.

Members of the federal advisory panel doubled down on long-refuted links between vaccines and autism during discussions on research funding.

Records obtained by AP and The Guardian show the health secretary's trip to Samoa involved MMR vaccine discussions, contradicting his sworn testimony.

The senator's report raises scrutiny of mifepristone manufacturing oversight as Heidi Overton faces confirmation for FDA commissioner.

Tessier-Lavigne published new details hoping to refute allegations in a book claiming he published fraudulent results while at Genentech and Stanford.

The new venture aims to avoid typical biotech hurdles by focusing on cosmetic and dermatological data rather than pharmaceutical drug development.

The company offered a reporter the chance to receive and write about the treatment, which combines two existing drugs.

The pilot aims to test new approaches to chronic disease management for Medicare beneficiaries.

Reproductive and forensic psychiatrists warn that the high-profile case may create liability fears that reduce access to care for postpartum patients.

Drug companies are pursuing large IPOs and big-ticket M&A as the sector continues its recovery.

A physician argues the code intended to incentivize relationship-based primary care may not be achieving its goals.

Scientists who resigned from the CDC argue that ideological influence continues to undermine the agency's scientific mission.